Novel Reversible Inhibitors of Xanthine Oxidase Targeting the Active Site of the Enzyme
Antioxidants · 28.03.2023 · 12 (4) · 825
DOI: 10.3390/antiox12040825 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antioxidants, online erschienen am 28.03.2023. Verfasst von Rosario Rullo und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institute for the Animal Production Systems in the Mediterranean Environment, CNR, 80055 Portici, Italy. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: MUR (Italy), promotion and policy development fund of the National Research Programme (PNR)-DM737 of 25-06-2021, National Research Programme.
Abstract (Originalsprache)
Xanthine oxidase (XO) is a flavoprotein catalysing the oxidation of hypoxanthine to xanthine and then to uric acid, while simultaneously producing reactive oxygen species. Altered functions of XO may lead to severe pathological diseases, including gout-causing hyperuricemia and oxidative damage of tissues. These findings prompted research studies aimed at targeting the activity of this crucial enzyme. During the course of a virtual screening study aimed at the discovery of novel inhibitors targeting another oxidoreductase, superoxide dismutase, we identified four compounds with non-purine-like structures, namely ALS-1, -8, -15 and -28, that were capable of causing direct inhibition of XO. The kinetic studies of their inhibition mechanism allowed a definition of these compounds as competitive inhibitors of XO. The most potent molecule was ALS-28 (Ki 2.7 ± 1.5 µM), followed by ALS-8 (Ki 4.5 ± 1.5 µM) and by the less potent ALS-15 (Ki 23 ± 9 µM) and ALS-1 (Ki 41 ± 14 µM). Docking studies shed light on the molecular basis of the inhibitory activity of ALS-28, which hinders the enzyme cavity channel for substrate entry consistently with the competitive mechanism observed in kinetic studies. Moreover, the structural features emerging from the docked poses of ALS-8, -15 and -1 may explain the lower inhibition power with respect to ALS-28. All these structurally unrelated compounds represent valuable candidates for further elaboration into promising lead compounds.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute for the Animal Production Systems in the Mediterranean Environment, CNR, 80055 Portici, Italy.
- Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, 80131 Naples, Italy.
- Department of Pharmacy, "Drug Discovery" Laboratory, University of Naples Federico II, 80131 Naples, Italy.
- Department of Human Movement Sciences and Wellness, University of Naples "Parthenope", 80133 Naples, Italy.
ORCID-Profile: Carmen Cerchia, Virgilio Romanelli, Mariorosario Masullo, Antonio Lavecchia
Förderung
- MUR (Italy), promotion and policy development fund of the National Research Programme (PNR)-DM737 of 25-06-2021
- National Research Programme
Zitieren
APA
Rullo, R., Cerchia, C., Nasso, R., Romanelli, V., Vendittis, E., Masullo, M., & Lavecchia, A. (2023). Novel Reversible Inhibitors of Xanthine Oxidase Targeting the Active Site of the Enzyme. Antioxidants, 12(4), 825. https://doi.org/10.3390/antiox12040825
Vancouver
Rullo R, Cerchia C, Nasso R, Romanelli V, Vendittis E, Masullo M, et al. Novel Reversible Inhibitors of Xanthine Oxidase Targeting the Active Site of the Enzyme. Antioxidants. 2023;12(4):825. doi:10.3390/antiox12040825
BibTeX
@article{Rullo2023,
author = {Rullo, Rosario and Cerchia, Carmen and Nasso, Rosarita and Romanelli, Virgilio and Vendittis, Emmanuele De and Masullo, Mariorosario and Lavecchia, Antonio},
title = {Novel Reversible Inhibitors of Xanthine Oxidase Targeting the Active Site of the Enzyme},
journal = {Antioxidants},
year = {2023},
volume = {12},
number = {4},
pages = {825},
doi = {10.3390/antiox12040825}
}
EUVIMED